0001104659-24-075387.txt : 20240627 0001104659-24-075387.hdr.sgml : 20240627 20240627080133 ACCESSION NUMBER: 0001104659-24-075387 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240625 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240627 DATE AS OF CHANGE: 20240627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rezolute, Inc. CENTRAL INDEX KEY: 0001509261 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273440894 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39683 FILM NUMBER: 241075401 BUSINESS ADDRESS: STREET 1: 275 SHORELINE DRIVE, SUITE 500 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-206-4507 MAIL ADDRESS: STREET 1: 275 SHORELINE DRIVE, SUITE 500 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: AntriaBio, Inc. DATE OF NAME CHANGE: 20130114 FORMER COMPANY: FORMER CONFORMED NAME: FITS MY STYLE INC DATE OF NAME CHANGE: 20110104 8-K 1 tm2418270d1_8k.htm FORM 8-K
false 0001509261 0001509261 2024-06-25 2024-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

  

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 25, 2024

 

 

REZOLUTE, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

Nevada   001-39683   27-3440894

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

275 Shoreline Drive, Suite 500, Redwood City, CA 94065

(Address of Principal Executive Offices, and Zip Code)

 

650-206-4507

Registrant’s Telephone Number, Including Area Code

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On June 25, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain purchasers as identified therein (the “Purchasers”) relating to a private placement (the “Private Placement”), pursuant to which the Company agreed to sell to the Purchasers 1,500,000 shares of Common Stock (“Private Shares”) at a purchase price of $4.00 per share, which represents a premium to the Nasdaq consolidated closing bid price on June 25, 2024.

 

The closing of the Private Placement will take place upon satisfaction of the closing conditions set forth in the Securities Purchase Agreement. The gross proceeds of the Private Placement to the Company, are expected to be approximately $6.0 million. The Company intends to use the net proceeds from the Private Placement to fund clinical research and development and for working capital and general corporate purposes.

 

In connection with the Securities Purchase Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers. Pursuant to the Registration Rights Agreement, the Company will be required to file a resale registration statement (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) to register for resale the Private Shares within thirty days of receipt of payment, and to have such Registration Statement declared effective within 60 days after the signing date of the Securities Purchase Agreement in the event the Registration Statement is not reviewed by the SEC, or 90 days of the signing date in the event the Registration Statement is reviewed by the SEC. The Company will be obligated to pay certain liquidated damages to the Purchaser if the Company fails to file the Registration Statement when required, fails to cause the Registration Statement to be declared effective by the SEC when required, or if the Company fails to maintain the effectiveness of the Registration Statement. The Securities Purchase Agreement and Registration Rights Agreement also contain representations, warranties, indemnification and other provisions customary for transactions of this nature.

 

The Private Placement is exempt from the registration requirements of the Securities Act of 1933 (the “Securities Act”) pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and in reliance on similar exemptions under applicable state laws. The securities sold and issued in the Private Placement are not registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. Neither this Current Report on Form 8-K, nor the exhibits attached hereto, is an offer to sell or the solicitation of an offer to buy the securities described herein.

 

The foregoing summaries of the Securities Purchase Agreement and Registration Rights Agreement do not purport to be complete and are subject to, and qualified in their entirety by, the forms of Registration Rights Agreement and Securities Purchase Agreement which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending June 30, 2024.

 

This report is being filed pursuant to and in accordance with Rule 135c under the Securities Act. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Private Shares. Any offers of the Private Shares will be made only by means of a private offering memorandum, and are not being made to any person in any jurisdiction in which such offer, sale or solicitation is unlawful.

 

 

 

 

Item 3.02. Unregistered Sales of Equity Securities.

 

The information under Item 1.01 of this Current Report on Form 8-K regarding the Private Placement is incorporated herein by reference.

 

Item 7.01Regulation FD Disclosure.

 

On June 27, 2024, the Company issued a press release announcing the exercise of the underwriters’ option to purchase additional shares and entering into the concurrent private placement. The text of the press release is included as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

 

The information in Item 7.01 of this Current Report on Form 8-K, including the attached Exhibit 99.1 is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit Number   Description
99.1   Press Release dated June 27, 2024.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

Caution Concerning Forward-Looking Statements

 

This Current Report on Form 8-K may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements about the closing of the Private Placement and the anticipated use of proceeds of the offerings. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the uncertainties related to market conditions and the completion of the offerings on the anticipated terms or at all. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the period ended June 30, 2023, in the Company’s Quarterly Reports on Form 10-Q for the periods ended September 30, 2023, ended December 31, 2023, and ended March 31, 2024 and in the Company’s other reports filed with the SEC. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  REZOLUTE, INC.
     
DATE: June 27, 2024 By: /s/ Nevan Charles Elam
    Nevan Charles Elam
    Chief Executive Officer

 

 

 

 EX-99.1 2 tm2418270d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

 

Additional $6.7M in funding resulting in approximately $67M in gross proceeds

 

NEW YORK--(BUSINESS WIRE)--Jun. 27, 2024-- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that the underwriters of its previously announced public offering, which closed on June 24, 2024, have exercised an over-allotment option to purchase an additional 1,786,589 shares of the Company’s common stock at the public offering price of $4.00 per share, less underwriting discounts and commissions. After giving effect to the option closing, the total number of shares sold by the Company in the offering were 13,036,589 shares, which along with pre-funded warrants to purchase up to an aggregate of 3,750,000 shares of its voting common stock, resulted in aggregate gross proceeds to the Company of approximately $67 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

 

In addition, the Company has entered into an agreement for a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), of 1,500,000 shares of its common stock, at a sale price of $4.00 per share.

 

Jefferies and Cantor served as the joint book-running managers for the public offering. BTIG, Craig-Hallum, H.C. Wainwright & Co., Jones and Maxim Group LLC are acting as co-managers for the public offering.

 

A registration statement on Form S-3 (File No. 333-275562) relating to the public offering was filed with the Securities and Exchange Commission (the SEC) on November 22, 2023, and was declared effective by the SEC on November 29, 2023. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC. These documents are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the public offering may also be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388, or by email at prospectus_department@jefferies.com or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com

 

This press release is being filed pursuant and in accordance with Rule 135(c) under the Securities Act of 1933 and does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

 

 

 

Rezolute, Inc.

 

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, RZ358, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI).

 

Forward-Looking Statements

 

Any statements in this press release about the Company’s future expectations, plans and prospects, including statements regarding the public offering, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. These forward-looking statements include statements about the closing of the Private Placement and the anticipated use of proceeds of the offerings. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to market and other financial conditions, the potential completion of the public offering, satisfaction of customary closing conditions related to the public offering and other factors discussed in the “Risk Factors” section contained in the preliminary prospectus supplement and the reports that the Company files with the SEC. Any forward-looking statements represent the Company’s views only as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.

 

Contacts:

 

Rezolute, Inc. 

Christen Baglaneas 

cbaglaneas@rezolutebio.com 

508-272-6717

 

LHA Investor Relations 

Tirth T. Patel 

tpatel@lhai.com 

212-201-6614

 

 

 

 EX-101.SCH 3 rzlt-20240625.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 rzlt-20240625_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 rzlt-20240625_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2418270d1_ex99-1img001.jpg GRAPHIC begin 644 tm2418270d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 25, 2024
Entity File Number 001-39683
Entity Registrant Name REZOLUTE, INC.
Entity Central Index Key 0001509261
Entity Tax Identification Number 27-3440894
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 275 Shoreline Drive
Entity Address, Address Line Two Suite 500
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code 650
Local Phone Number 206-4507
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol RZLT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://rezolutebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports rzlt-20240625.xsd rzlt-20240625_lab.xml rzlt-20240625_pre.xml tm2418270d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2418270d1_8k.htm": { "nsprefix": "rzlt", "nsuri": "http://rezolutebio.com/20240625", "dts": { "schema": { "local": [ "rzlt-20240625.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rzlt-20240625_lab.xml" ] }, "presentationLink": { "local": [ "rzlt-20240625_pre.xml" ] }, "inline": { "local": [ "tm2418270d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://rezolutebio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2418270d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2418270d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://rezolutebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-075387-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-075387-xbrl.zip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tm2418270d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001509261 2024-06-25 2024-06-25 iso4217:USD shares iso4217:USD shares false 0001509261 8-K 2024-06-25 REZOLUTE, INC. NV 001-39683 27-3440894 275 Shoreline Drive Suite 500 Redwood City CA 94065 650 206-4507 false false false false Common Stock, par value $0.001 per share RZLT NASDAQ false